Opus Genetics, Inc. (IRD)
NASDAQ: IRD · Real-Time Price · USD
2.270
+0.040 (1.79%)
At close: Dec 5, 2025, 4:00 PM EST
2.140
-0.130 (-5.73%)
After-hours: Dec 5, 2025, 7:53 PM EST
Opus Genetics Stock Forecast
Stock Price Forecast
According to 6 professional analysts, the 12-month price target for Opus Genetics stock ranges from a low of $5.00 to a high of $9.00. The average analyst price target of $7.17 forecasts a 215.86% increase in the stock price over the next year.
Price Target: $7.17 (+215.86%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Opus Genetics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 4 | 4 | 4 |
| Buy | 0 | 0 | 0 | 1 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 5 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Initiates $7 | Buy | Initiates | $7 | +208.37% | Nov 25, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $9 | Strong Buy | Maintains | $9 | +296.48% | Nov 13, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $9 | Strong Buy | Maintains | $9 | +296.48% | Nov 7, 2025 |
| Wedbush | Wedbush | Buy Initiates $8 | Buy | Initiates | $8 | +252.42% | Oct 29, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Initiates $9 | Strong Buy | Initiates | $9 | +296.48% | Oct 16, 2025 |
Financial Forecast
Revenue This Year
13.74M
from 10.99M
Increased by 24.98%
Revenue Next Year
18.79M
from 13.74M
Increased by 36.80%
EPS This Year
-0.72
from -2.15
EPS Next Year
-0.39
from -0.72
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 16.0M | 31.5M | ||||
| Avg | 13.7M | 18.8M | ||||
| Low | 11.1M | 9.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 45.9% | 129.3% | ||||
| Avg | 25.0% | 36.8% | ||||
| Low | 0.7% | -28.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -0.69 | -0.30 | ||||
| Avg | -0.72 | -0.39 | ||||
| Low | -0.79 | -0.48 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.